Parkinson's disease (PD) is a genetically heterogeneous disorder and new putative disease genes are discovered constantly. Therefore, whole-exome sequencing could be an efficient approach to genetic testing in PD. To evaluate its performance in early-onset sporadic PD, we performed diagnostic exome sequencing in 80 individuals with manifestation of PD symptoms at age 40 or earlier and a negative family history of PD. Variants in validated and candidate disease genes and risk factors for PD and atypical Parkinson syndromes were annotated, followed by further analysis for selected variants. We detected pathogenic variants in Mendelian genes in 6.25% of cases and high-impact risk factor variants in GBA in 5% of cases, resulting in overall maximum diagnostic yield of 11.25%. One individual was compound heterozygous for variants affecting canonical splice sites in VPS13C, confirming the causal role of protein-truncating variants in this gene linked to autosomal-recessive early-onset PD. Despite the low diagnostic yield of exome sequencing in sporadic early-onset PD, the confirmation of the recently discovered VPS13C gene highlights its advantage over using predefined gene panels.
| INTRODUCTION
Among the neurodegenerative disorders, Parkinson's disease (PD) (MIM 168600) is the second most prevalent, affecting overall 1.6% of the population of Caucasian descent with 20% of all individuals reporting a positive family history. 1 Only 3% to 5% of all patients with PD are diagnosed before age 40. 2 This rare form of the disease is referred to as early-onset PD (EOPD) and a higher genetic contribution to disease risk is expected in this group. There is considerable genetic heterogeneity in PD with to date 11 confirmed genes with Mendelian inheritance and several putative Mendelian genes and risk factors for which either conflicting evidence exists or no replication in independent datasets has been reported yet. 3, 4 The strongest genetic risk factors for PD to date are variants in the beta-glucocerebrosidase (GBA) gene, which is implicated in autosomal-recessive Gaucher disease (MIM 606463). Heterozygous carriers of mutations in GBA were
shown to have a 4-to 5-fold increase in their risk of developing PD. 5 Finally, new disease-related genes are still discovered for PD, promoted especially by the introduction of new sequencing technologies.
Whole-exome sequencing (WES) has become a cornerstone of molecular diagnosis in genetic disorders. [6] [7] [8] Predefined gene panels and WES are routinely used for a large range of different disease types. Diagnostic yield is reported for different disorders to be in the range of 20% to 40%. 9 For PD patients in general and also EOPD, reports on exome sequencing are sparse and so far these studies have focused on using WES to discover new disease genes. [10] [11] [12] [13] [14] Only 2 studies specifically sequenced individuals with EOPD. 14, 15 Our aim was to assess the performance of WES in the challenging subset of PD patients with sporadic EOPD. The early onset of the disease suggests a genetic basis, but the lack of a family history of PD complicates the analysis in this group. Therefore, we screened a series of 80 sporadic EOPD cases of European ancestry with WES to investigate the diagnostic yield using stringent variant classification criteria.
| MATERIALS AND METHODS

| Samples
DNA from 80 participants from movement disorder specialty clinics in Czech Republic (Prague; n = 49, mean age at onset 34.9 years, 63.3% male) and Germany (Munich and Kassel; n = 31, mean age at onset 35.8 years, 67.8% male) was analyzed. Inclusion criterion was a diagnosis of PD with onset of symptoms at the age of ≤40 years and a negative family history of PD. Diagnosis of PD was based on the UK Brain Bank diagnostic criteria for PD. Study approval was obtained from the respective ethics review boards and all participants gave written informed consent.
| Definition of gene sets
To assess the diagnostic yield, we included validated genes causing PD or atypical Parkinson syndromes with Mendelian inheritance.
These include 3 loci with autosomal dominant (SNCA, LRRK2, VPS35) and 9 with autosomal-recessive or X-linked manner of transmission (PARK2, PINK1, PARK7, DNAJC6, ATP13A2, FBXO7, PLA2G6,   ATP6AP2, SYNJ1, RAB39B) . 3, 4, 16 Furthermore, we included GBA as a validated risk factor for PD. 
| Sanger sequencing
Variants detected in GBA were validated by Sanger sequencing of exons 8 to 11 using BigDyeTerminator chemistry 3.1 (ABI, Thermo
Fisher Scientific, California, USA) on an ABI 3730 sequencer with primers and conditions as described previously. 30 Splice variants in VPS13C were validated and assessed for cis-or trans-configuration
by Sanger sequencing of the affected individual and 1 unaffected child. 
| Molecular analysis of splice variants
The consequences of splice variants in VPS13C were analyzed on the cDNA level by Sanger sequencing and agarose gel electrophoresis.
Total RNA was extracted from whole blood of the affected individual 3 | RESULTS
| Screening of validated Mendelian PD genes and risk factors
Assuming an autosomal-recessive mode of inheritance, we detected bi-allelic pathogenic variants in known Mendelian PD genes (PINK1 and PARK2) in 2 individuals (Table 1A) . In both cases, the variants are (Table 1A) . 31 No pathogenic or likely pathogenic variants were found in VPS35 and SNCA. We detected 4 heterozygous variants in known autosomal-dominant Mendelian PD genes, which we classified as variants of unknown significance (VUS) or benign after reviewing currently available genetic, functional and in-silico data (Table 1A and detailed discussion in Table S3 ). The overall diagnostic yield for validated Mendelian PD genes in our cohort was 5% (4/80 individuals, basic demographic and clinical information is given in Table 2 ).
In GBA, we initially detected 4 different heterozygous rare variants in 5 individuals passing our filtering criteria. We identified 2 carriers of p.Asn409Ser (formerly annotated as N370S, not based on HGVS recommendations), 1 carrier of p.Leu483Pro (formerly annotated as L444P), and 1 carrier of p.Asp448His (formerly annotated as D409H). In addition, we found 1 carrier of the singleton proteintruncating variant p.Trp432Ter. We also detected carriers of 2 variants with frequencies of about 1% in the ExAC and gnomAD nonFinnish European ancestry dataset or in >8000 in-house control exomes: 10 individuals were heterozygous for p.Glu365Lys (formerly annotated as E326K) and 3 individuals were heterozygous for p.
Thr408Met (formerly annotated as T369M). Due to the presence of a highly homologous pseudogene (GBAP1 with 98% sequence homology), sequencing of GBA is challenging. We therefore used Sanger For header and abbreviations used also refer to sequencing Overall, we identified and confirmed 3 different heterozygous rare variants in GBA which we classify as strong risk factors for PD (Table 1B) . According to ClinVar, both missense variants have been described as pathogenic in neuropathic Gaucher disease and as risk factors for PD. Nonsense variants in GBA are rare, but have been identified in neuropathic Gaucher disease and in PD patients. [32] [33] [34] Further support for a role of such loss of function variants in PD risk is provided by evidence of reduced GBA enzymatic activity in PD patients. 35, 36 The common missense variants p.Glu365Lys and p. 
RT-PCR for M2 . Sequences represent the reverse strand. C, For both variants, consequences on splicing were analyzed using RT-PCR. For each variant, several mutant transcripts are detected, denoted as m1a, m1b, m2a, m2b and m2c. For variant M1, the PCR had an expected wildtype product size of 466 bp. For variant M2, the PCR had an expected wildtype product size of 509 bp. M1/M2 refers to the affected individual, wt/wt to an unrelated healthy control. The higher molecular size bands were also sequenced and were found to contain both wt and m1b or m2c sequence, respectively. D, Structure of mutant transcripts and consequence on protein level. Retained intronic sequence is indicated with a "+", the number of affected nucleotides, and green shading. Deleted exonic sequence is indicated with a "−", the number of affected nucleotides, and blue shading. 
| Confirmation of VPS13C as causal in autosomal-recessive PD
Recently, homozygous or compound heterozygous protein-truncating variants in vacuolar protein sorting 13C (VPS13C) were described as a rare cause of autosomal-recessive EOPD. 12 We identified 1 individual who was a compound heterozygote for variants affecting canonical splice sites in VPS13C (Table 1A) . Segregation analysis confirmed the compound heterozygous condition of the variants (Figure 1 ). Variant milder motor symptoms and disease progression than the initially reported cases for VPS13C, but still showed a rather rapid deterioration with response fluctuations and severe dyskinesias, psychiatric symptoms, and impaired cognition (Table 2) .
Including VPS13C in our diagnostic gene set raises the diagnostic yield for Mendelian PD genes to 6.25% and the overall diagnostic yield to 11.25%.
| Exploratory screening of putative PD genes
Apart from VPS13C, we did not identify pathogenic or likely pathogenic variants in any of the other not yet validated genes for Mendelian inheritance identified by sequencing in families. We also did not identify pathogenic or likely pathogenic variants in the candidate genes put forward by recent exome sequencing studies in PD. None of the variants previously reported in PD patients in these genes were detected in our study sample.
Concerning genes with conflicting evidence for Mendelian inheritance, we detected variants passing our initial filtering criteria in DNAJC13, EIF4G1, and GIGYF2 (Table S5) (Table S5 ).
| DISCUSSION
We applied diagnostic WES to a series of 80 sporadic EOPD cases and detected clearly pathogenic variants in known or candidate Mendelian PD genes in 6.25% of patients. Bi-allelic pathogenic variants with autosomal-recessive inheritance were detected in 3 individuals (3.75%). Heterozygous variants with autosomal-dominant inheritance were found in 2 individuals (2.5%). This diagnostic yield is lower compared to the application of WES in molecular diagnostics of rare disorders such as childhood-onset Mendelian disorders or ataxia with reported yields of 20% to 30%. [6] [7] [8] However, it is comparable to a recent study which used targeted next-generation sequencing to screen 8 PD genes in a population from southern Spain. 42 In their sample of 28 sporadic EOPD patients they detected 2 individuals with pathogenic mutations in Mendelian PD genes, resulting in a diagnostic yield of 7.1%.
Different factors contribute to the lower diagnostic yield for PD observed in our study. As we only included sporadic cases, our sample likely contains less monogenic cases than a sample of familial PD would. DNA of the parents of the sporadic cases was not available, so we could not screen trios for de-novo variation. Importantly, we used very strict criteria for frequency filtering and attributing pathogenicity to a variant, which likely reduced our yield compared to other studies. Currently, the classification of low penetrance variants, which may reach higher frequencies than our frequency cutoff, is challenging, because in-silico prediction tools are still prone to misclassification and high-throughput functional testing of putative causal variants is not readily available. Finally, WES technology is not perfect. A small set of genes and exons is not covered sufficiently, triplet repeat expansions cannot be analyzed, and the detection scope for structural variants and noncoding variants is limited. 43 However, all heterozygous deletions in PARK2 in our study were in accordance with results of a previous MLPA analysis, indicating that high coverage WES is able to detect CNVs reliably. 44 The location of CNV calls by ExomeDepth overlapped with the MLPA results, and manual inspection of the sequencing reads confirmed the exact size of the CNVs. This is in line with a previous study showing high sensitivity of up to 88% for depth-of-coverage-based calling of CNVs containing 3 or more exons. 45 GBA is an important risk factor and disease modifier for PD; therefore we included it in the diagnostic evaluation. Based on our experience, we recommend focusing on extremely high-quality variants for WES analysis of GBA to avoid false-positive variant calls due to the homologous pseudogene. In our study, the only false-positive variant had a considerably lower quality score in WES compared with all other variants detected in GBA (SAMtools variant quality score of 78 vs 225). This filtering did not lower the discovery rate as Sanger sequencing revealed no variants not seen in the WES high-quality variant calls. Overall, 5% of the patients carried rare variants in GBA with a strong effect and 16.25% carried low-frequency variants with small effects. Interestingly, we saw a population-specific difference:
28.6% of cases from the Czech Republic carried variants in GBA, whereas only 9.7% of cases recruited in German centers did. The difference was mainly driven by the low-risk variant p.Glu365Lys, which was found in 9 Czech patients (18.4%), and only 1 German patient (3.2%), but also all carriers of rare variants in GBA were Czech patients. For none of the patients in our study, a Jewish background was reported. Our observations are in line with previous studies, which scanned the entire gene and showed population-specific frequencies between 4.2% and 9.8% for GBA carriers in PD cases of non-Ashkenazi Jewish ancestry. 5, 46 The targeted next-generation sequencing study from Spain had detected GBA variants in 17.8% of their EOPD cases and other studies focused on EOPD showed frequencies of 11.4% in a Greek sample and 25% in a sample from the United Kingdom. 47, 48 To our knowledge, we are the first study to report a high frequency of GBA variants in Czech EOPD patients. To fully evaluate the role of these variants as risk factors for PD in the Czech population, sequencing of GBA in matched controls is required to determine allele frequencies in unaffected individuals. For GBA, we found a statistically significant enrichment of variants passing our filtering criteria in our EOPD samples compared to in-house control exomes with an OR of 5.2, in line with previous observations. 5 The role of heterozygous variants in PARK2 in PD is still a matter of debate. Targeted sequencing studies have reported an increased frequency of carriers of heterozygous variants in PARK2 in PD patients compared to healthy controls. 31 This is in contrast to results of larger case-control sequencing efforts which did not detect an enrichment of such variants in PD patients. 49 We did not observe a statistically significant enrichment in our sample. However, due to its small sample size it has only moderate power for association analyses and also may lead to biased frequency estimates. Therefore, definite conclusions on the importance of heterozygous variants in PARK2 for PD should be drawn based on larger datasets.
Finally, our study highlights the advantage of WES compared with using predefined gene panels, which are lagging behind in integrating newly discovered genes. We were able to confirm for the first time the recently identified autosomal-recessive Mendelian PD gene VPS13C. Bi-allelic truncating variants in this gene were described as a very rare cause of rapidly progressing EOPD with early cognitive decline. 12 We detected 1 individual who carried compound heterozygous canonical splice-site mutations in VPS13C.
In conclusion, we achieved a diagnostic yield of 6.25% when focusing solely on Mendelian PD genes. We could increase the yield to 11.25% when including rare high-impact risk variants in GBA. Adding also low-frequency low-impact variants in GBA would raise the yield to 27.5%. However, the high frequency of GBA variants was specific to the Czech EOPD sample and is therefore not generalizable to WES in other populations. In terms of genetic counseling, GBA should be considered a risk factor for PD rather than a causal Mendelian gene. Penetrance estimates of 15% to 29.7% at the age of 80 years for heterozygous variants in GBA indicate that the majority of carriers of GBA variants never develop PD. [50] [51] [52] At present, it is not understood which additional genetic and environmental factors are necessary to develop PD in carriers of GBA variants. Counseling of affected individuals and families should be provided by specialized clinical geneticists who are qualified to evaluate and interpret the available clinical and genetic data.
Despite the comparably low diagnostic yield for Mendelian PD genes, exome sequencing should be the preferred approach for genetic testing of a patient presenting with EOPD. WES enables fast integration of new genetic findings into molecular diagnostics and the data can be reanalyzed at any time, which has been shown to improve diagnostic rate dramatically. 53 Finally, the inclusion of WES data in large-scale research projects is straightforward and has the potential to contribute to not only a better understanding of PD genetics and etiology, but also to accelerate the development of new and personalized treatment options.
